Elemental Formula denied as experimental or investigational by Humana?

Humana's specific coverage criteria for elemental formula are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Elemental Formula as Experimental — and How to Appeal

An "experimental" or "investigational" denial signals that Humana's medical policy reviewers have determined the elemental formula does not meet their threshold for accepted medical practice for your specific indication. This determination is often based on how Humana's internal policy defines "experimental" — which may rely on older evidence summaries or narrow diagnostic criteria — rather than on a current, individualized review of your case. For many diagnoses where elemental formula is used, substantial clinical evidence and society guideline support exists that directly contradicts an experimental classification.

## Why This Denial Is Appealable

Experimental/investigational denials are frequently overturned when the appeal documents that the treatment has mainstream clinical acceptance for the patient's specific condition. The key is showing that recognized medical authorities — relevant professional society guideline organizations, published clinical consensus, and the clinical literature — support elemental formula for your diagnosed condition. Humana's own definition of "experimental" typically excludes treatments with this level of support, meaning the denial may misclassify your situation.

## Your Federal Appeal Rights

• Internal appeal: ERISA §503 (employer plans) or state insurance law guarantees a full-and-fair internal review. File within 180 days of the denial date as shown on the denial notice.
• External review: Under ACA §2719, a final internal denial qualifies for independent external review, generally within four months of that final decision. The external reviewer's finding is binding on Humana.
• Expedited option: If delay creates serious clinical risk — for example, a patient who cannot absorb nutrients without elemental formula — request expedited internal and external review simultaneously.

## What to Gather Before You File

1. Denial letter — the exact experimental/investigational policy Humana cited and the indication it evaluated. 2. Humana's experimental-treatment policy — request the full policy document. Your appeal must engage with Humana's own definition criteria. 3. Prescriber's medical-necessity and standard-of-care letter — should assert that elemental formula is an accepted, non-experimental treatment for your diagnosed condition and reference the relevant guideline organization (e.g., the applicable pediatric gastroenterology, gastroenterology, or clinical nutrition society) that supports its use. 4. Diagnosis and workup records — chart notes confirming your diagnosis, the clinical basis for that diagnosis, and the clinical indicators driving the prescribing decision. 5. Prior-treatment history — dates and outcomes of any alternative nutritional interventions tried before elemental formula was recommended. 6. FDA regulatory status — confirm and document the regulatory classification of the specific formula product prescribed; elemental formulas are generally regulated medical foods, which is relevant to any experimental characterization.

## Criteria-Mapping Structure

| Humana Experimental-Policy Criterion | Your Rebuttal Evidence | |---|---| | Treatment lacks mainstream clinical acceptance | [Prescriber letter + guideline organization citation] | | Indication matches a covered, non-experimental use | [Diagnosis records + chart notes with ICD code] | | Alternative treatments tried or not appropriate | [Prior treatment history with dates/outcomes] | | Regulatory / classification status appropriate | [Product regulatory documentation] |

An appeal that works through Humana's experimental-policy language criterion by criterion — paired with a strong prescriber letter citing recognized guideline organizations — gives both the internal reviewer and any external reviewer a clear basis for overturning the denial.